Skip to main content

Table 2 Oncological characteristics of patients receiving SACT

From: Safe provision of systemic anti-cancer treatment for urological cancer patients during COVID-19: a tertiary centre experience in the first wave of COVID-19

  2019 (n = 518) 2020 (n = 441) (n2020n2019)/n2019 (%) p value
n % N %
Cancer type
 Prostate 340 65.64 292 66.21 14.12 0.851
 Renal 121 23.36 101 22.90 16.53 0.867
 Urothelial 42 8.11 38 8.62 9.52 0.776
 Testicular 15 2.90 10 2.27 33.33 0.543
Stage
 1 7 1.35 2 0.45 71.43 0.161
 2 11 2.12 6 1.36 45.45 0.368
 3 36 6.95 9 2.04 75.00 < 0.0001*
 4 463 89.38 423 95.92 8.64 < 0.0001*
 Missing 1 0.19 1 0.23 0.00 0.271
SACT
 Chemotherapy 112 21.62 71 16.10 36.61 0.0278
 Immunotherapy (IO) 43 8.30 50 11.34 − 16.28 0.110
 Hormone 244 47.10 236 53.51 3.28 0.0455
 Biological/targeted 102 19.69 67 15.19 34.31 0.0574
 Combo (Chemo/hormone) 9 1.74 2 0.45 77.78 0.0574
 Combo (Chemo/IO) 1 0.19 1 0.23 0.00 0.920
 Combo (Chemo/target) 0 0.00 1 0.23 N.A 0.271
 Combo (IO/Hormone) 1 0.19 0 0.00 100.00 0.368
 Combo (IO/target) 5 0.97 13 2.95 − 160.00 0.0214
 Combo (Chemo/IO/hormone) 1 0.19 0 0.00 100.00 0.368
Treatment paradigm
 Neoadjuvant 11 2.12 6 1.36 45.45 0.368
 Adjuvant 17 3.28 6 1.36 64.71 0.0574
 Radical 18 3.47 1 0.23 94.44 0.00194*
 Palliative 470 90.73 419 95.01 10.85 0.0124
 Curative 2 0.39 9 2.04 − 350.00 0.0164
Line of palliative treatment (2019, n = 470; 2020, n = 419)
 1 94 20.00 117 27.92 − 24.47 0.00194*
 2 248 52.77 257 61.34 − 3.63 0.00137*
 3 87 18.51 30 7.16 65.52  < 0.0001*
 4 26 5.53 10 2.39 61.54 0.0278
 5 11 2.34 3 0.72 72.73 0.0574
 6 2 0.43 2 0.48 0.00 0.841
 7 1 0.21 0 0.00 100.00 0.368
 Missing 1 0.21 0 0.00 100.00 0.368
Trial treatment
 Yes 64 12.36 52 11.79 18.75 0.790
SACT initiated during study period
 Yes 118 22.78 102 23.13 13.56 0.898
  1. *Statistically significant p values after Bonferroni correction for multiple comparisons